Results 101 to 110 of about 109,922 (297)

Two causes of COVID‐19‐related myocardial injury‐associated cardiogenic shock: Myocarditis and microvascular thrombosis

open access: yes
ESC Heart Failure, Volume 12, Issue 2, Page 1514-1522, April 2025.
Takamasa Iwai   +4 more
wiley   +1 more source

Diagnosis and Treatment of Myocarditis

open access: yes, 2013
Myocarditis is a clinical syndrome, most frequently of infectious etiology, that occurs with a broad range of relatively non-specific symptoms, and consists of an inflammatory process of the heart with necrosis and degeneration of the myocardium by ...

core   +2 more sources

Mortality risk stratification for Takotsubo syndrome: Evaluating CRP measurement alongside the InterTAK prognostic score

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1427-1436, April 2025.
Abstract Background and objectives Initially described as a benign acute cardiomyopathy, Takotsubo syndrome has been linked to elevated mortality rates. Emerging evidence suggests that unresolved myocardial inflammation may contribute to this adverse prognosis.
Loïc Faucher   +12 more
wiley   +1 more source

Ketogenic diet for infantile epileptic spasms

open access: yesEpilepsia Open, EarlyView.
Abstract Approximately half of all cases of Infantile Epileptic Spasms Syndrome (IESS) do not respond to vigabatrin and hormonal therapies. There is no clear consensus as to the second‐line therapy for IESS. Ketogenic diet (KD) has emerged as an effective treatment for certain drug‐resistant epilepsies and in many cases of IESS.
Morris H. Scantlebury   +3 more
wiley   +1 more source

Current Diagnosis and Management of Myocarditis

open access: yes, 2017
Myocarditis is an inflammation of the myocardium. The clinical presentations of myocarditis range from nonspecific systemic symptom such as fever, myalgias, palpitations, or exertional dyspnea, to severe hemodynamic derangement and sudden death. The wide
Mumpuni, Hasanah   +2 more
core   +1 more source

Tolerability of Adjuvant Nivolumab in Esophageal or Gastroesophageal Junction Cancer: A Real‐World Study

open access: yesInternational Journal of Cancer, EarlyView.
ABSTRACT Adjuvant nivolumab is approved for esophageal or gastroesophageal junction cancer after neoadjuvant chemoradiotherapy and resection. In the CheckMate‐577 trial, Grade 3–5 nivolumab‐related adverse events (AEs) occurred in 5% of patients, with early discontinuation due to toxicity in 9%. However, real‐world data on immunotherapy‐related adverse
Michelle Koops van ’t Jagt   +7 more
wiley   +1 more source

cfDNA methylation detection as potential liquid biopsy of multiple organ injury in myocarditis patients

open access: yesClinical Epigenetics
Myocarditis is inflammatory injury of the myocardium and causes approximately 30,000 deaths globally each year. Fulminant myocarditis is an extremely severe form of myocarditis.
Yangchao Zhao   +21 more
doaj   +1 more source

Incidence and Predictors of Immune‐Related Hypothyroidism Under Pembrolizumab Across Gynecologic Malignancies and Melanoma: A Real‐World Cohort Study

open access: yesInternational Journal of Cancer, EarlyView.
ABSTRACT Immune checkpoint inhibitors (ICIs) frequently cause thyroid immune‐related adverse events (irAEs). Permanent hypothyroidism, the clinically most relevant phenotype, requires lifelong hormone replacement. We investigated its incidence, course, risk factors, and prognostic relevance under pembrolizumab.
Freya Koffka   +9 more
wiley   +1 more source

Phenytoin-induced Stevens–Johnson syndrome with myocarditis: a rare case report

open access: yes, 2017
Ashwin Kodliwadmath Department of Medicine, Belgaum Institute of Medical Sciences, Belgaum, India Abstract: Stevens–Johnson syndrome (SJS) is an acute life-threatening mucocutaneous reaction caused by excessive necrosis and detachment of the ...
Kodliwadmath A
core  

Activity of Low Dose Nivolumab in Patients With Advanced Squamous Cell Carcinomas and Other Cancers

open access: yesInternational Journal of Cancer, EarlyView.
ABSTRACT Immune checkpoint inhibitors such as anti–PD‐1 antibodies are essential in cancer therapy. Emerging data suggest that lower doses may be effective and more economical, though further evidence is needed. We conducted a retrospective study at Centre Léon Bérard to assess the efficacy and safety of low‐dose nivolumab (20 mg every 3 weeks) in ...
Thibault Gauduchon   +16 more
wiley   +1 more source

Home - About - Disclaimer - Privacy